Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694653 | 0.94 | GRM1 (0.43) | MEN1KMT2APOLBTP53MAPT | |
| SCHEMBL4689303 | 0.91 | MEN1 (0.40) | MEN1KMT2ACNR2POLBTP53 | |
| SCHEMBL4691279 | 0.87 | GRM1 (0.38) | MEN1KMT2ACNR2POLBTP53 | |
| SCHEMBL4692246 | 0.85 | GRM1 (0.39) | MEN1KMT2ACNR2TP53MAPT | |
| SCHEMBL4692988 | 0.85 | GRM1 (0.41) | MEN1KMT2ACNR2TP53MAPT | |
| SCHEMBL4689299 | 0.85 | GRM1 (0.45) | MEN1KMT2APOLBTP53MAPT | |
| SCHEMBL5542947 | 0.84 | GRM1 (0.36) | MEN1KMT2ACNR2POLBTP53 | |
| SCHEMBL4691975 | 0.84 | GRM1 (0.36) | MEN1KMT2ACNR2POLBMAPT | |
| SCHEMBL4693608 | 0.84 | GRM1 (0.46) | MEN1KMT2ATP53MAPTALDH1A1 | |
| SCHEMBL4691276 | 0.81 | GRM1 (0.44) | MEN1KMT2APOLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | MEN1 2545/4885KMT2A 832/4885CNR2 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.